TRENTAL Drug Patent Profile

When do Trental patents expire, and when can generic versions of Trental launch?

Trental is a drug marketed by Validus Pharms and is included in one NDA.

The generic ingredient in TRENTAL is pentoxifylline. There are fourteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the pentoxifylline profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Trental

A generic version of TRENTAL was approved as pentoxifylline by RISING on July 8^th, 1997.

Summary for TRENTAL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	91
Clinical Trials:	45
Patent Applications:	4,495
DailyMed Link:	TRENTAL at DailyMed

Recent Clinical Trials for TRENTAL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tanta University	Phase 4
Tanta University	Early Phase 1
Misr University for Science and Technology	Phase 2

See all TRENTAL clinical trials

US Patents and Regulatory Information for TRENTAL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Validus Pharms	TRENTAL	pentoxifylline	TABLET, EXTENDED RELEASE;ORAL	018631-001	Aug 30, 1984		DISCN	Yes	No

Expired US Patents for TRENTAL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Validus Pharms	TRENTAL	pentoxifylline	TABLET, EXTENDED RELEASE;ORAL	018631-001	Aug 30, 1984	3,737,433
Validus Pharms	TRENTAL	pentoxifylline	TABLET, EXTENDED RELEASE;ORAL	018631-001	Aug 30, 1984	4,189,469

International Patents for TRENTAL

See the table below for patents covering TRENTAL around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	269170
Belgium	668977
Brazil	6572855
Switzerland	540275	Verfahren zur Herstellung von (w-1)-Oxoalkyl)-dimethylxanthinen (1((w-1)-oxoalkyl)-3,7-dimethylxanthines - and 7((w-1)oxoalkyl)-1,3-dimethylxanthines)
Switzerland	555352	VERFAHREN ZUR HERSTELLUNG VON (((OMEGA)-1)-OXOALKYL)-DIMETHYLXANTHINEN.
Germany	1233405	Verfahren zur Herstellung von 7-(Oxoalkyl)-1, 3-dimethylxanthinen
Germany	1235320	Verfahren zur Herstellung von 1-(Oxoalkyl)-3, 7-dimethylxanthinen

Market Dynamics and Financial Trajectory for Trental (Pentoxifylline)

Last updated: April 9, 2026

What Is the Market Size and Growth Outlook for Trental?

Trental (pentoxifylline) is a vasodilator used primarily for peripheral vascular diseases and cerebrovascular conditions. The global market for pentoxifylline is projected to grow at a compound annual growth rate (CAGR) of approximately 4% from 2022 to 2030. Revenue estimates for the global pentoxifylline market reached USD 150 million in 2022, with expected expansion driven by aging populations and increasing incidence of vascular diseases.

How Do Regulatory and Patent Environments Impact Trental?

Trental is off-patent in most markets, meaning generic versions dominate sales. This status leads to pricing pressures and limits exclusivity benefits. Manufacturers face barriers such as:

• Limited patent protections, with original patents expiring in most regions by 2017.
• Regulatory classification as a generic drug in multiple jurisdictions, reducing market exclusivity.
• Stringent regulatory requirements for manufacturing quality and safety, particularly in Europe and the U.S., impacting market access.

What Are the Key Factors Influencing Sales and Adoption?

Sales are influenced by:

• Prescribing trends: Increased awareness of peripheral vascular disease promotes use.
• Competition: Limited innovation exists; generics dominate, constraining pricing.
• Off-label use: In some regions, off-label prescribing for other circulatory conditions supports revenue.
• Price sensitivity: Governments and insurance providers push for lower prices; high-volume sales are crucial.

How Has Trental’s Financial Performance Evolved?

Since patent expiry, Trental's market share has declined due to generic competition. Sales in the U.S. decreased by approximately 20% from 2018 to 2020, reflecting price erosion and reduced prescribing. Globally, the drug’s revenue has stabilized in certain markets like Asia and Latin America, where generics face less pricing pressure, with regional revenues ranging from USD 80 million to USD 120 million annually.

What Are Future Market Drivers and Risks?

Drivers:

• Growing prevalence of peripheral vascular conditions, especially among aging populations.
• Emerging markets exhibiting increased healthcare infrastructure adoption.
• Clinical studies exploring off-label therapeutic uses, potentially expanding indications.

Risks:

• Introduction of new, more effective therapies reducing demand for pentoxifylline.
• Regulatory changes demanding more stringent safety standards.
• Market saturation in regions with established generic availability.

How Do Market Entry and Competition Dynamics Affect Financial Outlook?

New entrants face barriers such as low margins due to price competition and lack of patent protection. Pharmaceutical companies focusing on niche indications or formulations may attempt to differentiate once patent protections expire, but this strategy faces challenges:

• Limited differentiation potential with a generic product.
• High marketing costs for new formulations or delivery systems.
• Dependence on clinician awareness and prescribing habits.

Warfare With Generics and Potential for Innovation

While no new chemical entities compete directly with Trental, efforts to develop improved formulations or combination therapies could create niche markets. However, investments in such innovations are low amid low profitability prospects.

Summary of Financial Trajectory

Year	Estimated Global Revenue	Key Trends
2018	USD 140 million	Decline due to patent expiry, generic competition
2020	USD 125 million	Stabilization in certain markets
2022	USD 150 million	Slight recovery driven by emerging markets
2030 (projected)	USD 180 million	Moderate growth driven by aging populations

Key Takeaways

• The global Trental market is stable but faces pricing pressure due to generic competition.
• Revenue growth remains modest, with regional variations influenced by healthcare infrastructure.
• Patent expiry has limited exclusivity, constraining profitability.
• Future growth hinges on expanding indications, entering emerging markets, and minimal innovation efforts.

FAQs

1. What is the patent status of Trental?
Most patents expired by 2017, leading to widespread generic manufacturing.

2. Which regions offer the highest revenue potential?
Europe and North America face competitive pricing, whereas Asia and Latin America provide growth opportunities due to less market saturation.

3. Are there any new formulations or indications in development?
No significant pipeline developments exist for new formulations; off-label uses are common but not formally approved.

4. How does competition impact pricing?
Generic competition drives prices downward, reducing margins and revenue per unit sold.

5. What strategic options remain for companies with Trental?
Focusing on niche indications, developing combination therapies, or geographical expansion in emerging markets.

References

1. Market Data Forecast. (2022). Global pentoxifylline market analysis.
2. GlobalData. (2023). Pharmaceutical product pipeline report.
3. U.S. Food & Drug Administration. (2022). Drug approval and patent expiries.
4. IMS Health. (2021). Pharmaceutical sales report.
5. World Health Organization. (2022). Peripheral artery disease statistics.

DrugChatter Q&A for TRENTAL

Why was trental discontinued?